Equities research analysts expect that Edwards Lifesciences Corp (NYSE:EW) will post sales of $931.15 million for the current quarter, Zacks reports. Nine analysts have issued estimates for Edwards Lifesciences’ earnings. The lowest sales estimate is $910.00 million and the highest is $961.30 million. Edwards Lifesciences posted sales of $883.50 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 5.4%. The business is expected to announce its next earnings report after the market closes on Tuesday, April 24th.
According to Zacks, analysts expect that Edwards Lifesciences will report full year sales of $3.85 billion for the current financial year, with estimates ranging from $3.80 billion to $3.91 billion. For the next financial year, analysts forecast that the company will post sales of $4.19 billion per share, with estimates ranging from $4.05 billion to $4.36 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Edwards Lifesciences.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.91 by $0.03. The business had revenue of $888.50 million during the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. Edwards Lifesciences’s revenue was up 15.7% compared to the same quarter last year. During the same period last year, the business earned $0.75 EPS.
A number of brokerages have recently commented on EW. Cowen reiterated a “buy” rating and issued a $165.00 price target on shares of Edwards Lifesciences in a research note on Tuesday, March 20th. SunTrust Banks reiterated a “buy” rating and issued a $180.00 price target on shares of Edwards Lifesciences in a research note on Tuesday, April 10th. Zacks Investment Research lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. Barclays lifted their price target on shares of Edwards Lifesciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Finally, Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $145.92.
In related news, VP Larry L. Wood sold 6,300 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $121.00, for a total transaction of $762,300.00. Following the completion of the sale, the vice president now directly owns 116,148 shares in the company, valued at $14,053,908. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $127.24, for a total transaction of $674,372.00. Following the sale, the vice president now owns 24,908 shares of the company’s stock, valued at $3,169,293.92. The disclosure for this sale can be found here. Insiders have sold 197,236 shares of company stock valued at $26,375,070 over the last 90 days. 1.84% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Spectrum Asset Management Inc. NB CA lifted its holdings in Edwards Lifesciences by 7.4% during the fourth quarter. Spectrum Asset Management Inc. NB CA now owns 5,795 shares of the medical research company’s stock valued at $653,000 after purchasing an additional 400 shares in the last quarter. LS Investment Advisors LLC lifted its holdings in Edwards Lifesciences by 6.0% during the fourth quarter. LS Investment Advisors LLC now owns 7,789 shares of the medical research company’s stock valued at $878,000 after purchasing an additional 440 shares in the last quarter. Resources Investment Advisors Inc. lifted its holdings in Edwards Lifesciences by 66.0% during the fourth quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 465 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its holdings in Edwards Lifesciences by 1.9% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 26,902 shares of the medical research company’s stock valued at $2,953,000 after purchasing an additional 500 shares in the last quarter. Finally, Park Avenue Securities LLC lifted its holdings in Edwards Lifesciences by 16.5% during the fourth quarter. Park Avenue Securities LLC now owns 3,548 shares of the medical research company’s stock valued at $396,000 after purchasing an additional 503 shares in the last quarter. Institutional investors own 82.98% of the company’s stock.
NYSE:EW traded up $0.28 on Wednesday, reaching $138.12. 1,481,403 shares of the stock traded hands, compared to its average volume of 1,332,024. Edwards Lifesciences has a 12 month low of $93.67 and a 12 month high of $143.22. The firm has a market cap of $28,949.67, a P/E ratio of 36.35, a P/E/G ratio of 2.02 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.80.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Edwards Lifesciences Corp (EW) Will Announce Quarterly Sales of $931.15 Million” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/16/zacks-analysts-anticipate-edwards-lifesciences-corp-ew-will-announce-quarterly-sales-of-931-15-million.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Get a free copy of the Zacks research report on Edwards Lifesciences (EW)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.